Streetbeat News

Revenues

ALLY

Ally Financial (NYSE:ALLY) reported Q4 2023 earnings per share of $0.45, meeting analyst consensus estimates. Quarterly sales were $2.10 billion, surpassing the expected $2.00 billion by 5.22%, but representing a 2.91% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:26 pm

PRQR

ProQR Therapeutics presented new data on its Axiomer RNA editing technology, showing up to 70% editing of ACTB in the liver of non-human primates and mice. The platform's robust in vivo editing capabilities could have significant implications for the development of genetic treatments.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:12 pm

W

Wayfair anticipates delivering over $600M in Adjusted EBITDA for 2024, despite facing challenges in revenue growth due to persistent category weakness. The company will release full quarterly and annual results for the period ending December 31, 2023, during its February 2024 earnings call.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:10 pm

PEB

Pebblebrook Hotel Trust reported that their December operating results surpassed expectations, with a 7.1% year-over-year increase in same-property Hotel RevPAR and a 9.7% rise in non-room revenue.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:09 pm

PRQR

ProQR Therapeutics presented new data on its Axiomer RNA editing technology at Deaminet 2024, showing up to 70% editing efficiency in non-human primates and mice. The platform also demonstrated a functional effect in mice, with modulation of ANGPLT3 protein properties leading to an increase in LPL activity and a significant impact on biomarkers. Further data for pipeline programs AX-0810 and AX-1412 will be presented throughout 2024.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:06 pm

KIRK

Kirkland's reported a 3.1% increase in comparable sales for the first two months of fiscal Q4 ending December 30, 2023. This reflects a 1.5% rise in November and a 4.8% increase in December, year-over-year. The growth was attributed to robust in-store performance, with higher traffic and conversion rates.

Portfolio Pulse from Benzinga Newsdesk

January 19, 2024 | 12:04 pm

ACCD

Accolade (NASDAQ:ACCD) has received mixed ratings from 7 analysts over the last quarter, with recent sentiment showing 1 bullish rating in the last 30 days compared to 2 bullish and 2 somewhat bullish ratings 1 month ago. The 12-month price target average has increased to $14.71, up 8.96% from the previous $13.50, with a high estimate of $17.00 and a low of $12.00. Analysts from firms including Needham, Truist Securities, Piper Sandler, Wells Fargo, Raymond James, and Stifel have updated their ratings and price targets, reflecting their views on Accolade's market performance and financials. Accolade's financial indicators show a positive revenue trend with a growth rate of 9.26% as of November 30, 2023, but it has a net margin of -21.2% and ROE of -4.83%, indicating potential profitability and efficiency challenges.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 12:01 pm

DKNG

In the past three months, 17 analysts have provided ratings for DraftKings (NASDAQ:DKNG), with a majority being bullish. The average 12-month price target is now $44.76, up from $40.00, with high and low estimates of $50.00 and $28.00 respectively. Analysts have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. DraftKings has shown significant revenue growth but struggles with profitability, as indicated by a net margin of -35.84% and an ROE of -31.11%. The company is active in online sports betting, iGaming, and operates an NFT marketplace.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 12:00 pm

OLED

Analyst ratings for Universal Display (NASDAQ:OLED) show varied opinions, with recent updates indicating both upgrades and a downgrade. The average 12-month price target is $204.00, up from $174.25. The company faces revenue challenges with a -12.13% decline over 3 months but maintains a high net margin of 36.34%. Its market capitalization is below industry benchmarks, and it has a low debt-to-equity ratio of 0.02. Analysts' actions and price target adjustments reflect their views on the company's performance and market conditions.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 12:00 pm

EE

Analysts have mixed opinions on Excelerate Energy (NYSE:EE), with recent ratings ranging from bullish to bearish. Over the last quarter, 6 analysts provided ratings, with 4 somewhat bullish and 2 indifferent. The average 12-month price target is $23.67, down 7.18% from previous estimates. Key analysts from firms like Raymond James, Wells Fargo, Capital One, and Morgan Stanley have adjusted their ratings and price targets. Excelerate Energy's financial health shows a negative revenue trend with a -65.71% decline over 3 months, a net margin of 5.04%, an ROE of 2.8%, an ROA of 0.48%, and a debt-to-equity ratio of 1.69.

Portfolio Pulse from Benzinga Insights

January 19, 2024 | 12:00 pm